Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 5Pancreatic Ductal Adenocarcinoma (PDAC) 1Neoplasm Metastasis 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 30Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × folfirinox × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡